Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07241546 | Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma | PHASE2 | RECRUITING | 36 | — | — | Mar 30, 2026 | Apr 1, 2028 | May 28, 2026 | 2 | Canada |
| NCT05533294 | Study of ARO-RAGE in Healthy Subjects | PHASE1 | COMPLETED | 43 | — | — | Nov 29, 2022 | Feb 8, 2024 | Mar 29, 2024 | 1 | New Zealand |
| NCT05276570 | Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease | PHASE1 | COMPLETED | 127 | — | — | Jun 29, 2022 | Apr 16, 2025 | Apr 9, 2026 | 8 | Australia, New Zealand +3 |
| Arm | Type | Description |
|---|---|---|
| ARO-RAGE | EXPERIMENTAL | ARO-RAGE inhalation |
| Placebo | PLACEBO_COMPARATOR | Normal saline (0.9%) |
| Name | Type | Description |
|---|---|---|
| ARO-RAGE | DRUG | Inhalation of nebulized solution |
| Placebo | DRUG | Calculated volume to match active treatment by inhalation of nebulized solution |
| ARO-RAGE Injection | DRUG | ARO-RAGE injection for sc administration |
Inclusion Criteria: * Clinically stable, mild atopic asthma (FEV1 ≥70% predicted) * Established allergy confirmed by positive skin prick test at screening * Willing and able to perform lung function tests and other study-related procedures * Participants of childbearing potential must consent to us...